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Abstract
Colorectal cancer (CRC) stands for 10% of the worldwide cancer burden and has 
recently become the second most common cause of cancer death. The 5-year survival 
rate depends mainly on stage at diagnosis. Mass spectrometric proteomic analysis is 
widely used to study the plasma proteome, which is complex and contains multitudes 
of proteins. In this study, we have used Ultra Performance Liquid Chromatography-
Ultra Definition Mass Spectrometry (UPLC-UDMSE)-based proteomics to analyze 
plasma samples from 76 CRC patients. We identified several plasma proteins, such 
as CP, TVP23C, FETUB, and IGFBP3, of which altered levels led to significant 
differences in survival, as seen by Cox regression and Kaplan-Meier analysis. 
Additionally, during Cox regression analysis, samples were adjusted for age and/or 
tumor stage, enabling stringent analysis. These proteins, although in need of further 
validation, could be of use during patient follow-up, as their levels can non-invasively 
be measured from blood samples, and could be of use in predicting patient outcome. 
Several of these proteins additionally have roles in metabolism and inflammation, 
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1 |  INTRODUCTION
In 2018, over 1.8 million new cases of colorectal cancer 
(CRC) and closer to 900 000 deaths were estimated to have 
occurred, meaning that CRC stands for 10% of the global 
cancer burden. CRC is the third most common cancer and 
has risen to become the second most common cause of cancer 
death, behind only lung cancer. The highest incidence rates 
are found in Europe, North America, and Oceania, with in-
cidence rates being lower in Africa, South-Central Asia, and 
Central America. The overall 5-year survival rate for CRC 
patients is around 65%, and the 5-year survival rate depends 
heavily on stage at diagnosis.1,2 Per stage, 5-year survival is 
over 90% for stage I disease, 82.5% for stage II disease, 59.5% 
for stage III disease, and only 8.1% for stage IV disease. 
Around 20% of patients with stage II local disease and no 
lymph node metastasis will develop recurrence, and of those 
with lymph node metastasis but no distant metastasis, around 
half will develop recurrence.3,4
Stage at diagnosis is the most important prognostic factor 
for CRC.5 The anatomically based TNM staging system, al-
though widely used, struggles to clearly distinguish groups of 
patients with different prognosis among stage II and III CRC 
patients, particularly in those who receive adjuvant chemo-
therapy.6 For stage III CRC patients, an overall survival bene-
fit has been established for fluorouracil-based chemotherapy, 
although for patients with stage II CRC, the use of adjuvant 
chemotherapy is controversial. Studies have failed to demon-
strate a significant overall survival benefit in stage II CRC 
patients who receive adjuvant therapy, and current guidelines 
do not support its routine use.7,8
Currently, mass spectrometric proteomic analysis is 
widely used in efforts to analyze samples such as plasma. 
The plasma proteome is dynamic and reflects the state of 
the host due to the perfusion of organs. It therefore also 
reflects the presence of diseases such as cancer which can 
add, subtract, or modify circulating proteins.9,10 Proteomic 
analysis by mass spectrometry therefore enables the identi-
fication of differentially expressed proteins in plasma.11,12 
The plasma proteome is also ideal to study due to its com-
plexity, as it encompasses many different types of proteins. 
True plasma proteins that carry out their functions in the 
circulation, proteins secreted by tissues and tumors, pro-
teins that serve as messengers between tissues, temporary 
passengers, proteins that leak from tissues as a result of cell 
death or damage, and foreign proteins are all part of the 
plasma proteome.13
Previous proteomic studies of CRC have mainly investi-
gated serum or plasma proteins that could be of use in the 
early detection and diagnosis of CRC by comparing samples 
from healthy controls to samples from CRC patients.14-17 
Several studies have also identified proteins of value as 
potential prognostic markers for CRC patients by studying 
tissue samples.18,19 One study by Surinova et al employed 
proteomic profiling of 80 glycoprotein biomarker candidates 
and subsequently discovered a six-protein biomarker signa-
ture that could predict patient survival.20 In this study, we 
have used Ultra Performance Liquid Chromatography-Ultra 
Definition Mass Spectrometry (UPLC-UDMSE)-based pro-
teomics to analyze plasma samples from 76 CRC patients. 
The aim of this study was to discover proteins whose levels 
differed significantly between patients with good and poor 
long-term survival, as these proteins may be of future clinical 
utility.
2 |  MATERIALS AND METHODS
2.1 | Patient samples
This study used preoperative plasma samples from a total of 
76 CRC patients who underwent surgical resection with cura-
tive intent at the Department of Surgery, Helsinki University 
Hospital, between 2000 and 2007. Plasma samples were 
stored at −80°C until processed as described below. Patients 
with a previous history of non-colorectal cancer, hereditary 
nonpolyposis colorectal cancer, familial adenomatous poly-
posis, ulcerative colitis, Crohn's disease, or mucinous tumors 
were deliberately excluded from this study. Detailed patient 
characteristics are given in Table S1. The clinical data were 
obtained from patient records, the survival data from the 
Population Register Centre of Finland, and the cause of death 
for all the deceased from Statistics Finland. Written informed 
consent was obtained from all patients prior to collecting 
samples. This study was approved by the Surgical Ethics 
Committee of Helsinki University Hospital (Dnro HUS 226/
E6/06, extension TMK02 §66 17.4.2013) and carried out in 
accordance with the Declaration of Helsinki.
two processes central to the development and progression of cancer, further indicat-
ing their importance in cancer.
K E Y W O R D S
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2.2 | Sample processing and digestion
The plasma samples were processed as previously described21 
and as follows. Samples were thawed and top 12 protein de-
pletion was performed using the TOP12 protein depletion 
kit (Pierce, ThermoFisher) according to the manufacturer's 
instructions. The total protein concentration was determined 
using the Pierce BCA assay kit (Pierce, ThermoFisher). The 
amount of plasma equivalent to 100 µg of protein was ali-
quoted and dried using a SpeedVac (Savant, ThermoFisher), 
and the dried plasma was then dissolved in 35 µL Tris buffer 
(50 mmol/L, pH 7.8) containing 6 mol/L urea. 1.8 µL of dith-
iothreitol (DTT, 200 mmol/L) was then added to each sample 
and the samples were shaken for 1 hour at room temperature, 
after which 7 µL of iodoacetamide (200 mmol/L) was added 
to each sample. Samples were again shaken for 1 hour at room 
temperature, after which 7  µL of DTT (200  mmol/L) was 
added to each sample to quench excess iodoacetamide and 
prevent overalkylation. The samples were shaken for 1 hour 
at room temperature, after which they were diluted by adding 
270 µL mQ water per sample. Trypsin was added at a ratio 
of 1:50 trypsin to protein and the samples were digested at 
37°C overnight. The next day, 30 µg of tryptic peptides were 
cleaned using C18 spin columns (Pierce, ThermoFisher) and 
the cleaned peptides were dissolved in 86 µL of 0.1% formic 
acid containing 12.5 fmol/µL of Hi3 spike-in standard pep-
tides (Waters) for quantification.
2.3 | Ultra performance liquid 
chromatography-ultra definition mass 
spectrometry and quantification
2.3.1 | UPLC-UDMSE
UPLC-UDMSE was performed as previously described.21 
Data were acquired in data-independent acquisition fashion 
using UDMSE mode using a Synapt G2-S HDMS (Waters 
Corporation) and collected in the range of 100-2000  m/z, 
scan time one second, IMS wave velocity 650 m/s. Collision 
energy was ramped from 20 to 60  V and calibration was 
performed with sodium iodide clusters over a mass range of 
50-2500 m/z by infusing 2 µg/µL sodium iodide solution in 
50/50 2-propanol/water into the mass spectrometer. 10% of 
the samples were run in triplicate and the median coefficient 
of variation (%CV) of the dataset was 4.36%.
2.4 | Data analysis
Data analysis and label-free quantification were performed 
as previously described.21-23 In summary, the raw files 
were imported to Progenesis QI for proteomics (Nonlinear 
Dynamics). Post-acquisition mass correction was done 
when the raw data were imported into Progenesis with a 
lock mass ion of M+H+ 556.2771 m/z. Leucine enkephalin 
(C25H37O7, 1 ng/µL in 50:50 acetonitrile:water + 0.1% for-
mic acid) was infused into the reference sprayer at 300 nL/
min for this purpose. Default parameters were used for peak 
picking and alignment, while the peptide identification 
was done against Uniprot human FASTA sequences (re-
lease 2018_04). A ClpB protein sequence (CLPB_ECOLI 
(P63285)) was inserted for label-free quantification. Fixed 
modification at cysteine (carbamidomethyl) and variable at 
methionine (oxidation) were used. Trypsin was used as a di-
gesting agent, with one missed cleavage allowed. Fragment 
and peptide error tolerances were set to automatic settings, 
and the false discovery rate (FDR) was set to less than 2%. 
The default parameters for ion fragments required to identify 
peptides were used.
The parsimony principle was used to group the pro-
teins and peptides unique to the protein were also reported. 
Progenesis QI for proteomics does not follow a strict parsimo-
nious approach due to over-stringency, which has been pre-
viously noted.24 In the case of a conflict where two proteins 
were found with common peptides, the protein with fewer 
peptides is absorbed into the protein with more peptides. All 
relevant proteins are listed as a group under the lead protein 
with the highest coverage or score if the coverages of two or 
more proteins are equal. Quantitation was performed using 
the lead identity peptide data. Further details can be found 
on the Nonlinear Dynamics’ website (www.nonli near.com).
2.5 | Further analysis
The mass spectrometry proteomics data have been depos-
ited to the ProteomeXchange Consortium via the PRIDE25,26 
partner repository with the dataset identifier  PXD013150 
and 10.6019/PXD013150. Survival was analyzed using the 
Kaplan-Meier method, log-rank tests, and Cox proportional 
hazards regression analysis. Cox proportional hazards regres-
sion analysis was used for age- and stage-adjusted analyses. 
Cut-off values were determined by maximizing the absolute 
value of Youden's index from receiver operating characteris-
tics curves, thereby assigning equal weight on sensitivity and 
specificity.
3 |  RESULTS
3.1 | Protein identification and analysis
In this study, we analyzed plasma samples from 76 CRC 
patients (after the exclusion of one sample, marked in 
Table S1, that failed to digest properly). We quantified 
726 |   HOLM et aL.
224 proteins that contained two or more unique peptides, 
and these proteins were subsequently used for further 
analysis. All 224 proteins with their relevant data are 
given in Table S2.
3.2 | Analysis of all samples
Univariate Cox regression analysis was performed on all 
224 proteins quantified (Table S3). Five proteins passed 
T A B L E  1  The proteins with significant P-values when all samples were analyzed by univariate Cox regression
Accession Protein name Gene name P-value
Hazard 
ratio (HR) 95% CI (lower)
95% CI 
(upper)
B4E1Z4;P00751 cDNA FLJ55673, highly similar to 
Complement factor B
  0.00 0.59 0.421 0.840
P00450;Q96CS3;Q96L
14;Q99551;Q9BRC7
Ceruloplasmin CP 0.03 0.70 0.505 0.968
Q96ET8;Q9NYZ1 Golgi apparatus membrane protein 
TVP23 homolog
TVP23C 0.03 0.71 0.524 0.970
Q9UGM5 Fetuin-B FETUB 0.04 0.69 0.488 0.984
P17936 Insulin-like growth factor-binding 
protein 3
IGFBP3 0.05 0.73 0.533 0.993
Note: Accession, protein and gene name, P-value, HR, and lower and upper 95% CI are given in the table.
T A B L E  2  The top five proteins according to p-value when all samples were analyzed by univariate Cox regression and adjusted for age and 
stage
Accession Protein name Gene name P-value HR 95% CI (lower)
95% CI 
(upper)
Q9UGM5 Fetuin-B FETUB 0.033 0.67 0.462 0.968
P04180 Phosphatidylcholine-sterol 
acyltransferase
LCAT 0.053 0.72 0.516 1.004
B4E1Z4;P00751 cDNA FLJ55673, highly 
similar to Complement 
factor B
  0.065 0.70 0.474 1.022
P04196 Histidine-rich glycoprotein HRG 0.075 0.74 0.530 1.031
Q92777 Synapsin-2 SYN2 0.077 0.78 0.585 1.028
Note: One protein, fetuin-B, had a P-value of less than 0.05.
F I G U R E  1  The Kaplan-Meier curves for CP (A), TVP23C (B), and IGFBP3 (C) when all samples were analyzed. The cut-off was set at the 
maximum of Youden's index for each protein. In all figures, the long-term survival of CRC patients with plasma levels above the cut-off was better 
than for patients with levels below
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the cut-off of a Cox regression P-value of <.05: cDNA 
FLJ55673, highly similar to Complement factor B, cerulo-
plasmin (CP), golgi apparatus membrane protein TVP23 ho-
molog (TVP23C), fetuin-B (FETUB), and insulin-like growth 
factor-binding protein 3 (IGFBP3). These proteins are given 
with their relevant details in Table 1. The hazard ratio (HR) 
for these proteins was <1, indicating that high plasma lev-
els are correlated with favorable prognosis. Additionally, all 
samples were also adjusted for age and stage and analyzed by 
Cox regression. The top five proteins according to their Cox 
regression P-value are given in Table 2. Only one protein, 
FETUB, had a P-value of <0.05 (Table 2).
Kaplan-Meier curves were generated for each of the five 
proteins, including the cDNA identified (Figure S1A), with 
the cut-off set at the maximum of Youden's index for each 
protein. The differences in survival depending on plasma lev-
els of these proteins were significant (P < .05) as analyzed 
by log-rank tests for all proteins except FETUB (P = .068) 
(Figure S1B). The Kaplan-Meier curve for CP is shown 
in Figure 1A, for TVP23C in Figure 1B, and the curve for 
IGFBP3 is shown in Figure 1C. In all figures, the long-term 
survival of patients with plasma levels above the cut-off was 
better than for patients with levels below. The differences in 
outcome between the groups became even clearer as time 
passed.
3.3 | Analysis of stage II samples
Cox regression analyses were also performed when samples 
were divided according to tumor stage (II or III). Eight pro-
teins, given in Table S4, had significant p-values when only 
stage II samples were analyzed by Cox regression. Higher 
plasma levels of the same cDNA identified when all samples 
were compared, as well as CP and TVP23C, also predicted 
a better survival for stage II patients. Higher levels of two 
complement-related proteins, complement factor H (CFH) 
and Complement C3 (C3), were also found to be linked to 
a favorable outcome. These samples were also adjusted for 
age and analyzed by Cox regression again, after which 11 
significantly different proteins were identified (Table S5). 
Several of the proteins such as CP, TVP23C, CFH, and C3 
had significant P-values even without age-adjustment, al-
though other proteins such as piwi-like protein 4 (PIWIL4) 
and DEP domain-containing protein 1A (DEPDC1) had non-
significant p-values prior to age-adjustment.
Kaplan-Meier curves were drawn with the cut-off set 
at the maximum of Youden's index for each protein. The 
Kaplan-Meier curve for CFH, shown in Figure 2A, shows 
that higher plasma levels of CFH are linked to better long-
term survival (P  =  .019). For CP (Figure 2B), TVP23C 
(Figure 2C), and C3 (Figure 2D), the differences in survival 
F I G U R E  2  The Kaplan-Meier curves for CFH (A), CP (B), TVP23C (C), C3 (D), and FETUB (E) when only stage II samples were 
analyzed. The cut-off was set at the maximum of Youden's index for each protein. In all figures, the long-term survival of stage II CRC patients 
with plasma levels above the cut-off was better than for patients with levels below
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were also significant as seen in the Kaplan-Meier curves. 
However, only one to two patients with plasma levels above 
the cut-off for the protein in question died due to CRC, while 
multiple patients with levels below the cut-off died due to 
CRC, leading to slightly unbalanced groups. FETUB did not 
have a significant p-value when analyzed by Cox regression 
analysis when stage II samples were compared (P =  .053), 
although the Kaplan-Meier curve drawn (Figure 2E) showed 
significant differences in outcome as analyzed by log-rank 
test (P = .003).
3.4 | Analysis of stage III samples
When samples from only patients with stage III CRC were 
analyzed by Cox regression, five proteins had significantly 
different P-values (Table S4). Two of the proteins, MORC 
family CW-type zinc finger protein 2 (MORC2) and phos-
phatidylcholine-sterol acyltransferase (LCAT) had HRs of 
<1, indicating that high plasma levels of these two proteins 
predicted a favorable outcome. However, the HR for the other 
three proteins, mannose-binding protein C (MBL2), signal-
induced proliferation-associated 1-like protein 1 (SIPA1L1), 
and phosphatidylinositol-glycan-specific phospholipase D 
(GPLD1), were higher than 1, indicating that high plasma 
levels are a marker of poor survival for stage III CRC pa-
tients. These samples were also adjusted for age and analyzed 
by Cox regression, after which three proteins with signifi-
cant P-values were found (Table S5). Two of these proteins, 
LCAT and SIPA1L1, also had significant P-values prior to 
age-adjustment, indicating that they could be of value in pre-
dicting outcome. The third protein, ephrin type-A receptor 5 
(EPHA5), had a non-significant P-value prior to age-adjust-
ment, although higher levels were subsequently linked to a 
favorable outcome in stage III patients afterwards.
Again, Kaplan-Meier curves were drawn with the cut-
off set at the maximum of Youden's index for each protein. 
The Kaplan-Meier curve for SIPA1L1, shown in Figure 3A, 
confirms the findings by Cox regression analysis that higher 
plasma levels of SIPA1L1 are correlated with poor outcome 
in stage III CRC patients. Only two patients with plasma lev-
els of SIPA1L1 below the cut-off died due to CRC, compared 
to 25 patients with levels that were above the cut-off that died 
due to CRC. Although not significant when analyzed by Cox 
regression analysis (P = .08), Kaplan-Meier analysis showed 
that for stage III patients, higher plasma levels of the CNK3/
IPCEF1 fusion protein (CNK3/IPCEF1) lead to a signifi-
cantly (P = .006 as analyzed by log-rank test) poorer long-
term survival rate, especially as time progressed (Figure 3B).
4 |  DISCUSSION
In this study, we identified several plasma proteins that could 
aid in predicting the outcome of CRC patients. When all 
samples were analyzed by univariate Cox regression, higher 
levels of plasma proteins such as CP, TVP23C, FETUB, and 
IGFBP3 (P < .05) were each found to predict a favorable out-
come. When they were adjusted for both age and stage and 
re-analyzed, FETUB was the only protein with a significant 
F I G U R E  3  The Kaplan-Meier curves for SIPA1L1 (A) and CNK3/IPCEF1 (B) when only stage III samples were analyzed. The cut-off was 
set at the maximum of Youden's index for each protein. Plasma levels above the cut-off for both proteins are correlated with poor outcome in stage 
III CRC patients
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P-value. Additionally, Kaplan-Meier curves further sup-
ported these findings, showing that patients with high levels 
of CP, TVP23C, or IGFBP3 had a significantly higher long-
term survival rate (Figure 1). The difference in survival was 
not significant for patients with high or low levels of FETUB 
when analyzed by Kaplan-Meier. High levels of TVP23C 
were also found to correlate with a favorable outcome when 
stage II samples were analyzed separately, both before and 
after being adjusted for age. When stage III samples were 
analyzed separately by Cox regression, LCAT and SIPA1L1 
had significant p-values both before and after age-adjustment. 
High plasma levels of LCAT were correlated with a favora-
ble outcome, while high levels of SIPA1L1 were correlated 
with a poor outcome for stage III CRC patients. LCAT and 
FETUB are proteins involved in metabolism, with roles in 
lipid and glucose metabolism respectively. Metabolism is al-
tered in cancer cells, enabling their survival and proliferation, 
and the reprogramming of metabolism by cancer cells has 
been recognized as a hallmark of cancer.27,28
In concordance with our findings that higher levels of 
IGFBP3 were linked to a favorable outcome in this set of 
CRC patients, a previous study found that men with higher 
plasma levels of IGFBP3 had a lower risk of developing 
CRC.29 IGFBP3 binds insulin-like growth factors (IGFs) 
and subsequently influences proliferation by modeling the 
access of IGFs to their receptors, and has also been shown 
to induce apoptosis in a prostate cancer cell line through an 
IGF-independent mechanism.29,30 Serum levels of C3 have 
previously been found to be higher in CRC patients compared 
to healthy controls,31 implying that measuring levels of C3 
may aid in the diagnosis of CRC, although there are no pre-
vious studies investigating the value of C3 as a prognostic 
marker. Here, we found that higher plasma levels of C3 were 
linked to a favorable outcome, although only in stage II pa-
tients. CNK3/IPCEF1 is a fusion protein that is required for 
hepatocyte growth factor (HGF)-mediated Arf6 activation 
and HGF-dependent migration.32 Arf6 is a protein involved in 
cell adhesion and migration, and Arf6 activation is required 
for the motile phenotype of epithelial cells. Arf6 activation 
has been shown to be important for cancer cell proliferation, 
invasion, and metastasis in various cancers, with inhibition of 
Arf6 suppressing invasion and metastasis.33,34 This may help 
explain our findings that plasma levels of CNK3/IPCEF1 are 
higher in stage III CRC patients with poor outcome. To the 
best of our knowledge, it has not been previously shown that 
altered levels of proteins such as FETUB, TVP23C, LCAT, 
SIPA1L1, and CNK3/IPCEF1 are correlated with good or 
poor outcome in CRC patients.
This study was strengthened by the fairly large number 
of samples analyzed and the rigorous inclusion criteria used, 
where patients with other types of cancer and underlying 
diseases that likely affect plasma protein expression, such as 
inflammatory bowel disease, were excluded. This study was 
also strengthened by the well-characterized patient cohort and 
the long follow-up times for the patients included, as some 
CRC patients relapsed and eventually succumbed to their dis-
ease up to 9 years after their initial operation, and other pa-
tients were disease-free and were followed for up to 18 years 
after their operation. One limit of this study was the lack of 
validation of the proteins identified in an independent cohort 
of patients. Further validation and additional studies are nec-
essary to investigate if these plasma proteins can be of use in 
the clinic and why high or low levels are linked to longer or 
shorter survival times. Additionally, when samples were di-
vided according to stage, the number of patients in each group 
was reduced, which should also be taken into account.
One advantage of the proteins identified in this study is 
that because they are plasma proteins, their levels can non-in-
vasively be measured. However, the largest differences in 
long-term survival were seen after 10+ years of follow-up, 
indicating that while these proteins may be of use for monitor-
ing patient status, they may not be ideal for predicting relapse 
at an early stage. Additionally, as the proteins identified are 
plasma proteins and not tumor-specific proteins, their levels 
can also be affected by other conditions and diseases besides 
CRC, which must be taken into account. Here, we identified 
multiple plasma proteins such as CP, TVP23C, FETUB, and 
IGFBP3 that, after further studies and validation, could be 
measured during patient follow-up and monitoring to assist 
in predicting outcome.
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